Last reviewed · How we verify

Intravenous ondansetron

Mongi Slim Hospital · FDA-approved active Small molecule Quality 5/100

Intravenous ondansetron is a Small molecule drug developed by Mongi Slim Hospital. It is currently FDA-approved. Also known as: ondansetron.

At a glance

Generic nameIntravenous ondansetron
Also known asondansetron
SponsorMongi Slim Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intravenous ondansetron

What is Intravenous ondansetron?

Intravenous ondansetron is a Small molecule drug developed by Mongi Slim Hospital.

Who makes Intravenous ondansetron?

Intravenous ondansetron is developed and marketed by Mongi Slim Hospital (see full Mongi Slim Hospital pipeline at /company/mongi-slim-hospital).

Is Intravenous ondansetron also known as anything else?

Intravenous ondansetron is also known as ondansetron.

What development phase is Intravenous ondansetron in?

Intravenous ondansetron is FDA-approved (marketed).

Related